Inactive Instrument

Clal Biotechnology Industries Ltd. Share Price TEL AVIV STOCK EXCHANGE

Equities

CBI

IL0011042806

Investment Holding Companies

Financials

Sales 2022 370K 98.35K 8.2M Sales 2023 104K 27.64K 2.31M Capitalization 62.27M 16.55M 1.38B
Net income 2022 -61M -16.21M -1.35B Net income 2023 -31M -8.24M -687M EV / Sales 2022 331 x
Net Debt 2022 23.85M 6.34M 529M Net Debt 2023 22.4M 5.95M 497M EV / Sales 2023 814 x
P/E ratio 2022
-1.6 x
P/E ratio 2023
-2.01 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 34.65%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 51 01/15/01
Director of Finance/CFO 46 -
Chief Tech/Sci/R&D Officer 55 01/22/01
Members of the board TitleAgeSince
Chairman 67 09/03/09
Director/Board Member 71 18/15/18
Director/Board Member 73 17/20/17
More insiders
Clal Biotechnology Industries Ltd (CBI) is an Israel-based biotechnology investment company. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The Company is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.
More about the company